^
    Back
    Association details:
    Biomarker:RET mutation
    Cancer:Thyroid Gland Medullary Carcinoma
    Drug:SY-5007 (RET inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

    Excerpt:
    ...Patients with advanced tumor must have histological or cytological confirmed RET alteration, including NSCLC patients with RET-fusion or MTC patients with RET-mutation or other patients with RET alteration, and either have progressed after standard therapy or...
    Trial ID:
    NCT05278364
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    A first-in-human phase I, dose-escalation and dose-expansion study of SY-5007, a highly potent and selective RET inhibitor, in Chinese patients with advanced RET positive solid tumors.

    Published date:
    05/25/2023
    Excerpt:
    SY-5007 was well tolerated in patients. Preliminary antitumor activity was also observed in patients with advanced RET-fusion positive NSCLC and RET mutant MTC.
    DOI:
    10.1200/JCO.2023.41.16_suppl.9111
    Trial ID:
    NCT05278364